CR20120120A - Metodos para el tratamiento de un sarcoma utilizando un cambiador epimetabolico (coenzima q10) - Google Patents
Metodos para el tratamiento de un sarcoma utilizando un cambiador epimetabolico (coenzima q10)Info
- Publication number
- CR20120120A CR20120120A CR20120120A CR20120120A CR20120120A CR 20120120 A CR20120120 A CR 20120120A CR 20120120 A CR20120120 A CR 20120120A CR 20120120 A CR20120120 A CR 20120120A CR 20120120 A CR20120120 A CR 20120120A
- Authority
- CR
- Costa Rica
- Prior art keywords
- epimetabolic
- sarcoma
- methods
- coenzima
- changer
- Prior art date
Links
- 206010039491 Sarcoma Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 abstract 5
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 abstract 2
- 235000017471 coenzyme Q10 Nutrition 0.000 abstract 2
- 230000006696 biosynthetic metabolic pathway Effects 0.000 abstract 1
- 239000005515 coenzyme Substances 0.000 abstract 1
- 229940110767 coenzyme Q10 Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23684509P | 2009-08-25 | 2009-08-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20120120A true CR20120120A (es) | 2012-07-04 |
Family
ID=43730801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20120120A CR20120120A (es) | 2009-08-25 | 2012-03-13 | Metodos para el tratamiento de un sarcoma utilizando un cambiador epimetabolico (coenzima q10) |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20110064747A1 (enExample) |
| EP (1) | EP2470169A4 (enExample) |
| JP (2) | JP6159085B2 (enExample) |
| KR (1) | KR101572463B1 (enExample) |
| CN (2) | CN102548549A (enExample) |
| AU (2) | AU2010292532A1 (enExample) |
| BR (1) | BR112012004237A8 (enExample) |
| CA (1) | CA2772068C (enExample) |
| CR (1) | CR20120120A (enExample) |
| EA (1) | EA201270325A1 (enExample) |
| IL (1) | IL218306B (enExample) |
| IN (1) | IN2012DN01911A (enExample) |
| MX (1) | MX2012002208A (enExample) |
| SG (2) | SG178547A1 (enExample) |
| WO (1) | WO2011031503A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120034649A (ko) * | 2009-05-11 | 2012-04-12 | 버그 바이오시스템즈, 엘엘씨 | 환경대사적 전환인자(조효소 q10)를 사용한 질환의 치료 방법 |
| EP2694463B8 (en) | 2011-04-04 | 2019-10-09 | Berg LLC | Treating central nervous system tumors with coenzyme q10 |
| WO2014059008A1 (en) | 2012-10-09 | 2014-04-17 | The Procter & Gamble Company | Method of identifying or evaluating beneficial actives and compositions containing the same |
| CN104703585A (zh) | 2012-10-09 | 2015-06-10 | 宝洁公司 | 鉴定协同化妆品组合的方法 |
| US9138393B2 (en) | 2013-02-08 | 2015-09-22 | The Procter & Gamble Company | Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin |
| US9144538B2 (en) | 2013-02-08 | 2015-09-29 | The Procter & Gamble Company | Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin |
| MX380565B (es) | 2013-04-08 | 2025-03-12 | Berg Llc | Terapias combinadas de coenzima q10 para el tratamiento de cáncer. |
| MX381399B (es) | 2013-09-04 | 2025-03-12 | Berg Llc | Formulaciones de coenzima q10 y métodos de uso. |
| US10627392B2 (en) | 2014-06-17 | 2020-04-21 | Stealth Biotherapeutics Corp | Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening |
| US10527620B2 (en) * | 2014-07-07 | 2020-01-07 | Allergan, Inc. | Method of detecting cleaved SNAP25 in tissue samples |
| CN105044360A (zh) * | 2015-07-22 | 2015-11-11 | 浙江大学医学院附属邵逸夫医院 | Rbp4作为结直肠癌血清标记物的应用及诊断试剂盒 |
| US20170189350A1 (en) | 2015-11-16 | 2017-07-06 | Berg Llc | Methods of treatment of temozolomide-resistant glioma using coenzyme q10 |
| CN106053813A (zh) * | 2016-06-25 | 2016-10-26 | 林森 | 一种检测鼻咽癌pdk1表达量的免疫组化试剂盒及其应用 |
| CN106947010B (zh) * | 2017-04-06 | 2018-12-11 | 哈尔滨工业大学 | 一种利用光引发raft聚合原位诱导自组装制备蛋白质基纳米粒子的方法 |
| KR102682716B1 (ko) * | 2017-05-17 | 2024-07-08 | 비피지바이오, 인크. | 수포성 표피박리증의 치료 및 예방에서 조효소 q10 제형의 용도 |
| CN107226862A (zh) * | 2017-05-27 | 2017-10-03 | 南京川博生物技术有限公司 | 特异性人ews‑fli1融合蛋白抗体的制备方法及在制备尤文肉瘤诊断抗体试剂的应用 |
| US11216742B2 (en) | 2019-03-04 | 2022-01-04 | Iocurrents, Inc. | Data compression and communication using machine learning |
| US20230080670A1 (en) * | 2019-04-05 | 2023-03-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for treating tumors using transcription inhibition and dna damage |
| US20240141352A1 (en) * | 2021-03-05 | 2024-05-02 | University Of Central Florida Research Foundation, Inc. | Chaperonin-containing tcp-1 inhibitors for the treatment of cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000040749A2 (en) * | 1999-01-06 | 2000-07-13 | Genenews Inc. | Method for the detection of gene transcripts in blood and uses thereof |
| WO2003087404A1 (en) * | 2002-04-17 | 2003-10-23 | Novartis Ag | Methods to predict patient responsiveness to tyrosine kinase inhibitors |
| JP2006345701A (ja) * | 2003-07-01 | 2006-12-28 | Taisho Pharmaceut Co Ltd | タキサン類応答性の判別方法 |
| US20060035981A1 (en) * | 2003-08-02 | 2006-02-16 | Mazzio Elizabeth A | Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment |
| BRPI0507039A8 (pt) * | 2004-01-22 | 2018-12-18 | Univ Miami | composição, métodos de tratar um paciente com câncer, e de inibir a angiogênese em um tumor, e, kit |
| EP1756306A2 (en) * | 2004-05-14 | 2007-02-28 | Ludwig Institute For Cancer Research | Identification and characterization of a subset of glioblastomas sensitive to treatment with imatinib |
| WO2006125143A2 (en) * | 2005-05-18 | 2006-11-23 | Novartis Ag | Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2007026895A1 (ja) * | 2005-09-02 | 2007-03-08 | Toray Industries, Inc. | 尿路上皮ガンの検出用キットおよび方法 |
| EP1777523A1 (en) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| US8211634B2 (en) * | 2006-02-14 | 2012-07-03 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| US8030013B2 (en) * | 2006-04-14 | 2011-10-04 | Mount Sinai School Of Medicine | Methods and compositions for the diagnosis for early hepatocellular carcinoma |
| JP5147852B2 (ja) * | 2007-10-18 | 2013-02-20 | 株式会社メディカル・プロテオスコープ | 手術後の予後を推定する方法及び診断キット |
-
2010
- 2010-08-25 IN IN1911DEN2012 patent/IN2012DN01911A/en unknown
- 2010-08-25 US US12/868,678 patent/US20110064747A1/en not_active Abandoned
- 2010-08-25 EP EP10815861A patent/EP2470169A4/en not_active Withdrawn
- 2010-08-25 KR KR1020127007679A patent/KR101572463B1/ko not_active Expired - Fee Related
- 2010-08-25 CA CA2772068A patent/CA2772068C/en not_active Expired - Fee Related
- 2010-08-25 CN CN2010800427577A patent/CN102548549A/zh active Pending
- 2010-08-25 BR BR112012004237A patent/BR112012004237A8/pt not_active IP Right Cessation
- 2010-08-25 WO PCT/US2010/046711 patent/WO2011031503A2/en not_active Ceased
- 2010-08-25 EA EA201270325A patent/EA201270325A1/ru unknown
- 2010-08-25 JP JP2012526951A patent/JP6159085B2/ja not_active Expired - Fee Related
- 2010-08-25 SG SG2012012704A patent/SG178547A1/en unknown
- 2010-08-25 AU AU2010292532A patent/AU2010292532A1/en not_active Abandoned
- 2010-08-25 SG SG10201405069QA patent/SG10201405069QA/en unknown
- 2010-08-25 CN CN201711449284.2A patent/CN108245497A/zh active Pending
- 2010-08-25 MX MX2012002208A patent/MX2012002208A/es unknown
-
2012
- 2012-02-23 IL IL218306A patent/IL218306B/en not_active IP Right Cessation
- 2012-03-13 CR CR20120120A patent/CR20120120A/es unknown
-
2013
- 2013-01-24 US US13/749,337 patent/US20130266557A1/en not_active Abandoned
-
2015
- 2015-12-28 JP JP2015255646A patent/JP2016136938A/ja not_active Ceased
-
2016
- 2016-12-23 AU AU2016277749A patent/AU2016277749A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2772068C (en) | 2017-03-21 |
| CN102548549A (zh) | 2012-07-04 |
| WO2011031503A3 (en) | 2011-07-21 |
| WO2011031503A2 (en) | 2011-03-17 |
| EA201270325A1 (ru) | 2012-11-30 |
| EP2470169A2 (en) | 2012-07-04 |
| US20130266557A1 (en) | 2013-10-10 |
| EP2470169A4 (en) | 2013-03-13 |
| AU2010292532A1 (en) | 2012-04-05 |
| CA2772068A1 (en) | 2011-03-17 |
| JP6159085B2 (ja) | 2017-07-05 |
| AU2016277749A1 (en) | 2017-02-02 |
| MX2012002208A (es) | 2012-06-12 |
| BR112012004237A8 (pt) | 2016-10-04 |
| BR112012004237A2 (pt) | 2016-04-05 |
| IN2012DN01911A (enExample) | 2015-07-24 |
| CN108245497A (zh) | 2018-07-06 |
| US20110064747A1 (en) | 2011-03-17 |
| SG178547A1 (en) | 2012-03-29 |
| JP2016136938A (ja) | 2016-08-04 |
| KR101572463B1 (ko) | 2015-11-27 |
| JP2013503175A (ja) | 2013-01-31 |
| IL218306A0 (en) | 2012-04-30 |
| SG10201405069QA (en) | 2014-10-30 |
| IL218306B (en) | 2018-05-31 |
| KR20120050495A (ko) | 2012-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20120120A (es) | Metodos para el tratamiento de un sarcoma utilizando un cambiador epimetabolico (coenzima q10) | |
| MX349796B (es) | Composiciones farmacéuticas para usarse en el tratamiento de trastornos oncológicos mediante el uso de coenzima q10. | |
| PH12015502033A1 (en) | Leucine and nicotinic acid reduces lipid levels | |
| PH12015501660A1 (en) | Erk inhibitors and uses thereof | |
| TR201813877T4 (tr) | Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler. | |
| MX2019005692A (es) | Procesos para producir lipidos. | |
| DK2139477T3 (da) | Pyrazolopyridinderivater som NADPH-oxidaseinhibitorer | |
| HK1204908A1 (en) | Advanced methods, techniques, devices, and systems for cruciate retaining knee implants | |
| UA104927C2 (uk) | Стабілізація руху нестійких фрагментів космічного сміття | |
| CR20110002S (es) | Barra de chocolate | |
| DK2349261T3 (da) | Pyrazolopyridinderivater som NADPH-oxidaseinhibitorer | |
| AR065721A1 (es) | Derivados de piridazinona utiles como inhibidores de glucano sintasa. composiciones farmaceuticas. | |
| BR112013016204A2 (pt) | composições de ingredientes ativos solúveis em gordura que contêm complexos de proteína vegetal-polissacarídeo de soja. | |
| CL2015002473A1 (es) | Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida y su uso como inhibidores de la phd. | |
| MX2019009856A (es) | Activadores de cinasa de piruvato para su uso en terapia. | |
| ECSP14013302A (es) | Composiciones de yodo-povidona estable | |
| BRPI0922293A2 (pt) | rolamento radial de esferas, especialmente rolamento de esferas de carreira única | |
| BRPI0807897A2 (pt) | Derivados de pirimidina-2,4-diamina e seus usos como inibidores de jak2 quinase. | |
| LT3581654T (lt) | Būdai ir kompozicijos, skirti glikolato oksidazės (hao1) specifinei inhibicijai dvigrande rnr | |
| WO2011115809A3 (en) | High energy radiation insensitive analyte sensors | |
| BR112017028549A2 (pt) | derivados de pirimidina como inibidores de btk e usos dos mesmos | |
| EP2307575A4 (en) | UNTREATED ROLLING CIRCLE AMPLIFICATION PRODUCT | |
| CO2017002813A2 (es) | Derivados estabilizados de adrenomedulina y uso de los mismos | |
| CL2011000292A1 (es) | Compuestos derivados de enfumafungina y sus sales farmaceuticamente aceptables, como inhibidores de (1,3)-beta-d-glucano sintasa; composicion farmaceutica; y uso para tratar una infeccion fungica. | |
| IN2015DN03001A (enExample) |